GLOW vs KLOW
Both are multi-peptide preparations built on the same three-component base. KLOW adds a fourth peptide.
GLOW combines GHK-Cu, BPC-157 and TB-500. KLOW is that same base plus KPV, a tripeptide fragment of alpha-melanocyte-stimulating hormone studied for activity in inflammatory signalling.
Side by side
| GLOW | KLOW | |
|---|---|---|
| GHK-Cu | Yes | Yes |
| BPC-157 | Yes | Yes |
| TB-500 | Yes | Yes |
| KPV | No | Yes |
| Number of peptides | Three | Four |
| Research areas covered | Matrix remodelling, angiogenic signalling, cell migration | The same, plus inflammatory-pathway signalling |
| Solution appearance | Faintly blue (copper complex) | Faintly blue (copper complex) |
Choosing between them
Researchers choose GLOW when
the three-component base covers the mechanisms under study — matrix, vascular and migration. It is the simpler preparation and the lower cost per vial.
Researchers choose KLOW when
inflammatory signalling is also in scope. KPV is the reason to step up; without that interest, the additional component adds cost without adding relevance.
Common questions
What does the K in KLOW stand for?
What is KPV?
Why is the solution blue?
This comparison covers structure, receptor targets and development stage — matters of published record. It does not rank the compounds or claim either produces better outcomes. Much of the supporting literature is preclinical. All products are supplied for laboratory research use only.